Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study

References

• Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001;161:45–52
   PubMed Web of Science ®Google Scholar
• Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252–8
   PubMed Web of Science ®Google Scholar
• Dean BB, Crawley JA, Schmitt CM, et al. The burden of illness of gastro-osephageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003;17:1309–17
   PubMed Web of Science ®Google Scholar
• Moss SF, Armstrong D, Arnold R, et al. GERD 2003 – A consensus on the way ahead. Digestion 2003;67:111–7
   Web of Science ®Google Scholar
• Horn J. The proton-pump inhibitors: Similarities and differences. Clin Ther 2000;22:266–80
   PubMed Web of Science ®Google Scholar
• Vanderhoff BT, Tahboub RM. Proton pump inhibitors: An update. Am Fam Physician 2002;66:273–80
   PubMed Web of Science ®Google Scholar
• Desai CA, Samant BD. Rabeprazole. J Postgrad Med 2002; 48:80–1
   PubMedGoogle Scholar
• Hungin APS, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463–4
   Google Scholar
• Morii M, Takata H, Fujisaki H, et al. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18–5364 to inhibit gastric H+,K(+)-ATPase is correlated with the rate of acid- activation of the inhibitor. Biochem Pharmacol 1990;39:661–7
   PubMed Web of Science ®Google Scholar
• Kromer W, Krüger U, Huber R, et al. Differences in pH- dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998;56:57–70
   PubMed Web of Science ®Google Scholar
• Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438–46
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Shibata H, Oketani K, et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991;42:321–8
   PubMed Web of Science ®Google Scholar
• Pantoflickova D, Dorta G, Ravic M, et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003;17:1507–14
   PubMed Web of Science ®Google Scholar
• Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20mg, or esomeprazole, 20mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002;16:1301–7
   PubMed Web of Science ®Google Scholar
• Holtmann G, Bytzer P, Metz M, et al. A randomized, doubleblind, comparative study of standard-dose rabeprazole and highdose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:479–85
   PubMed Web of Science ®Google Scholar
• Adachi K, Hashimoto T, Hamamoto N, et al. Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 2003;18:1392–8
   PubMed Web of Science ®Google Scholar
• Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med 1999;72:93–100
   PubMed Web of Science ®Google Scholar
• Veldhuyzen van Zanten SJO, Tytgat KMAJ, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993;46:273–9
   PubMed Web of Science ®Google Scholar
• Robinson M, Fitzgerald S, Hegedus R, et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002;16:445–54
   PubMed Web of Science ®Google Scholar
• Cloud ML, Enas N, Humphries TJ, et al. Rabeprazole in treatment of acid peptic diseases. Results of three placebocontrolled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998;43:993–1000
   Google Scholar
• Dekkers CPM, Beker JA, Thjodleifsson B, et al. Doubleblind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13: 49–57
   Google Scholar
• Watanabe Y, Fujiwara Y, Shiba M, et al. Cigarette smoking and alcohol consumption associated with gastro-oesophageal reflux disease in Japanese men. Scand J Gastroenterol 2003;38:807–11
   PubMed Web of Science ®Google Scholar
• Delchier J-C, Cohen G, Humphries TJ. Rabeprazole, 20mg once daily or 10mg twice daily, is equivalent to omeprazole, 20mg once daily, in the healing of erosive gastro-oesophageal reflux disease. Scand J Gastroenterol 2000;35: 1245–50
   Google Scholar
• Castell DO, Johnston BT. Gastroesophageal reflux disease. Current strategies for patient management. Arch Fam Med 1996;5:221–7
   PubMedGoogle Scholar
• Mössner J, Höhscher AH, Herz R, et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9:321–6
   PubMed Web of Science ®Google Scholar
• Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview. Can J Gastroenterol 1997;11 (Suppl B):6B–73
   Google Scholar
• Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656–65
   PubMed Web of Science ®Google Scholar
• Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575–83
   PubMed Web of Science ®Google Scholar
• Labenz J, on behalf of the EXPO study group, Keeling N, Eklund S. A comparison of esomeprazole 40 mg once-daily and pantoprazole 40 mg once-daily for the healing of reflux oesophagitis. Poster presented at United European Gastroenterology Week, November 1–5, 2003, Madrid, Spain
   Google Scholar
• Howden CW, Ballard ED, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive esophagitis. Clin Drug Invest 2002;22: 99–109
   Google Scholar
• Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003;18:559–69
   PubMed Web of Science ®Google Scholar
• Raghunath AS, Green JR, Edwards SJ. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis. Clin Ther 2003;25:2088–102
   Google Scholar
• Carswell GI, Goa KL. Rabeprazole. An update of its use in acid- related disorders. Drugs 2001;61:2327–56
   Google Scholar